Healthcare
Live Price
Offline$400.00
-57.46% today
Window Change
-50.06%
Window
Jun 23, 2025 โ Mar 18, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 186 bars ยท Jun 23, 2025 โ Mar 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is a Healthcare stock with a market cap of $814.59B. The stock last traded around $400.00 and down 50.1% across the available one-year price window (Jun 23, 2025 โ Mar 18, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +178.5%, a dividend yield of 4.4%. What stands out right now is revenue -0.2%, EPS +178.5%, free cash flow -7.9% with operating margin 25.7% and ROIC 13.5%. The dividend matters to the case here, with a current yield around 4.4%. Valuation is more restrained than many high-expectation growth names at P/E 16.0 and price/sales 2.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines BMYMP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.2% vs +7.6% peer median
Operating Margin
Above sector median
+25.7% vs +19.4% peer median
P/E
Below sector median
16.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 5, 2026 with an EPS surprise of +2.4% and a revenue surprise of +1.8%.
The operating picture looks softer than before
Revenue is at -0.2% and EPS is at +178.5%, with operating margin around 25.7%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.6% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 5, 2026 | +2.4% | +3.6% | +3.6% | +2.6% |
2025 Oct 30, 2025 | +1083.5% | +0.0% | +4.2% | +16.1% |
2025 Jul 31, 2025 | +882.6% | +0.0% | +0.0% | +2.0% |
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BMYMP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
BMYMP Max Drawdown
-61.90%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BMYMP and SPY.
Company Overview
Bristol-Myers Squibb Company PFD CONV 2
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.